Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ionis Pharmaceuticals, Inc.    IONS


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ionis Pharmaceuticals : Akcea Therapeutics - WAYLIVRA, the first and only therapy for familial chylomicronaemia syndrome, to be available on the NHS in Scotland

11/10/2020 | 09:32am EST

LONDON - Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Scottish Medicines Consortium (SMC) has enabled access to volanesorsen on the National Health Service (NHS) in Scotland for the treatment of familial chylomicronaemia syndrome (FCS).1

This decision will allow patients in Scotland with this rare and life-threatening condition to access the treatment through NHS Scotland. SMC's acceptance follows recent approval from the National Institute for Health and Care Excellence (NICE) for the use of volanesorsen on the NHS in England.2

Volanesorsen was evaluated by the SMC under the ultra-orphan medicines pathway, a new system for the assessment of medicines for extremely rare diseases, which was introduced at the start of this year. This means that eligible patients will be able to access volanesorsen through NHS Scotland while additional clinical effectiveness data are gathered. The SMC will review this data after three years and make a final decision on its routine use in NHS Scotland.

'Today's announcement is an incredibly important milestone for those living with FCS in Scotland,' said Andy Caldwell, Country Manager, UK & Ireland at Akcea Therapeutics UK. 'We welcome this innovative new pathway in Scotland that allows treatments for extremely rare conditions that meet specific criteria, to be evaluated under the ultra-orphan medicines pathway. This allows patients with extremely rare conditions to benefit from access to much-needed treatments. As no other treatments are currently available for FCS in Scotland, this is a landmark moment for this patient population and it moves us forward on our journey to ensure patients with the rarest conditions, such as FCS, are not left behind.'

FCS is an under-recognised condition characterised by extremely high triglyceride levels (10 to 100 times normal values) and abnormal accumulation of lipoprotein particles called chylomicrons in the blood.3,4 FCS can put the patient at an increased risk of recurrent episodes of potentially fatal acute pancreatitis, as well as chronic abdominal pain and long term morbidity.3 Volanesorsen is the first and only treatment for FCS currently available to patients in the UK.

There are only one to two cases of FCS for every one million people, making the condition incredibly rare.5 FCS is also associated with a breadth of cognitive impairments, significant emotional burden, and poor mental health.4,5 There is no cure, and the condition is currently managed by adopting a very strict low-fat diet of 10 to 20g of fat per day.4 This is incredibly challenging and does not remove the risk of pancreatitis and other symptoms of the condition.7

Volanesorsen will be the second treatment that Akcea Therapeutics has made available on the NHS in Scotland in the past 18 months. Volanesorsen, a product of Ionis' proprietary antisense technology, is designed to reduce the production of ApoC-III, a protein that regulates plasma triglycerides and may also affect other metabolic parameters.6,9

WAYLIVRA (volanesorsen) was granted conditional marketing authorisation in May 2019 by the European Commission.8

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk/. Alternatively, search for MHRA Yellow Card in the Google Play or Apple App Store or contact the MHRA at yellowcard@mhra.gov.uk or 0800 731 6789 (10am to 2pm Monday to Friday only).

About volanesorsen

Volanesorsen, which received conditional marketing authorisation in Europe in May 2019, is the only therapy indicated for people with familial chylomicronaemia syndrome (FCS). It was recommended for use in the treatment of FCS in routine care on the NHS by the National Institute for Health and Care Excellence (NICE) in England in September 2020.2 Volanesorsen is a self-administered, subcutaneous injection in a single-use, prefilled syringe.

Volanesorsen, a product of Ionis' proprietary antisense technology, is designed to reduce the production of ApoC-III, a protein that regulates plasma triglycerides and may also affect other metabolic parameters.8,9 The European Commission's marketing authorisation of volanesorsen was based on results from the Phase 3 APPROACH study10 and the ongoing APPROACH Open Label Extension (OLE) study9, and is supported by results from the Phase 3 COMPASS study.11 Results from the Phase 3 APPROACH trial, the largest study ever conducted in patients with FCS, show that in comparison to placebo, following three months of treatment, volanesorsen reduced triglycerides by 94%. All patients in the trial maintained a low-fat diet.9

Volanesorsen is associated with risk of thrombocytopenia. Enhanced monitoring is required to support early detection and management of thrombocytopenia. The most frequently observed adverse reactions (more than 10%) during treatment with volanesorsen were events associated with injection site reactions and reduction in platelet levels/thrombocytopenia.8,9

About FCS

FCS is an under-recognised condition caused by impaired function of the enzyme lipoprotein lipase, or LPL, and characterised by severe hypertriglyceridaemia (>880mg/dL or 10mmol/L) and a risk of potentially fatal acute pancreatitis.4 Because of limited LPL function, people with FCS cannot breakdown chylomicrons, lipoprotein particles that are 90% triglycerides.4 FCS, which is estimated to affect 3,000 to 5,000 patients worldwide, can lead to many health issues including chronic pain, fatigue, a milky appearance of retinal veins and arteries, neurological symptoms such as depression and memory loss, swelling of the liver and spleen, and fatty deposits in the skin.4


Akcea Therapeutics, Inc. is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA therapeutics. Akcea commercializes TEGSEDI (inotersen) and WAYLIVRA (volanesorsen), and with Ionis, is advancing a mature pipeline of novel medicines discovered by Ionis and based on Ionis' proprietary antisense technology. TEGSEDI is approved in the U.S., E.U., Canada and Brazil, and WAYLIVRA is approved in the E.U.


This press release includes forward-looking statements regarding Ionis' business, financial guidance and the therapeutic and commercial potential of WAYLIVRA (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' wholly owned subsidiary. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2019, and the most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of these and other documents are available from the Company.

Ionis Pharmaceuticals is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics TEGSEDI and WAYLIVRA are trademarks of Akcea Therapeutics, Inc.


Tel: +44 0203 928 6834

Email: sarah.herbert@evokegroup.com

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
AKCEA THERAPEUTICS, INC. 0.17% 18.17 End-of-day quote.0.00%
IONIS PHARMACEUTICALS, INC. -5.33% 59.19 Delayed Quote.4.69%
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
01/12IONIS PHARMACEUTICALS : 2021 JP Morgan Presentation
01/11BIOGEN : Announces First Patient Treated in RESPOND Study Evaluating Benefit of ..
01/08BIOGEN : Treats First Patient in Study of SPINRAZA to Treat Children With Spinal..
01/07IONIS PHARMACEUTICALS : Appoints Eugene Schneider as Chief Clinical Development ..
01/07IONIS PHARMACEUTICALS : appoints Eugene Schneider, M.D., as executive vice presi..
01/05IONIS PHARMACEUTICALS : to present at 39th Annual J.P. Morgan Healthcare Confere..
2020IONIS PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
2020IONIS PHARMACEUTICALS : Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to f..
2020IONIS PHARMACEUTICALS : UBS Starts Ionis Pharmaceuticals at Sell With $34 Price ..
More news
Financials (USD)
Sales 2020 710 M - -
Net income 2020 -74,6 M - -
Net Debt 2020 145 M - -
P/E ratio 2020 -117x
Yield 2020 -
Capitalization 8 276 M 8 276 M -
EV / Sales 2020 11,9x
EV / Sales 2021 10,6x
Nbr of Employees 817
Free-Float 95,0%
Duration : Period :
Ionis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IONIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 64,81 $
Last Close Price 59,19 $
Spread / Highest target 103%
Spread / Average Target 9,49%
Spread / Lowest Target -67,9%
EPS Revisions
Managers and Directors
Brett P. Monia Chief Executive Officer & Director
Stanley T. Crooke Executive Chairman
Joel Edwards Vice President-Corporate & Commercial Operations
Elizabeth L. Hougen Chief Financial Officer & SVP-Finance
C. Frank Bennett Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.49.07%60 120
LONZA GROUP AG5.49%50 227
CELLTRION, INC.-10.58%39 891
SEAGEN INC.-7.11%31 230